Document Detail


Effect of combined administration of growth hormone (GH)-releasing hormone, GH-releasing peptide-6, and pyridostigmine in normal and obese subjects.
MedLine Citation:
PMID:  7783658     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Growth hormone (GH) secretion in response to all provocative stimuli is decreased in patients with obesity. Recently, we found that the combined administration of GH-releasing hormone (GHRH) and the hexapeptide GH-releasing peptide-6 (GHRP-6) induced a large increase in plasma GH levels. To gain further insight into the disrupted mechanism of GH regulation in obesity, we investigated whether the inhibition of somatostatinergic tone with pyridostigmine could further increase the GH response to combined administration of GHRH and GHRP-6. In normal subjects, administration of GHRH plus GHRP-6 induced a marked increase in plasma GH with a peak at 30 minutes (mean +/- SEM, 76.7 +/- 9.7 micrograms/L), which was similar to that obtained after pretreatment with pyridostigmine (74.7 +/- 9.4 micrograms/L). In obese patients, combined administration of GHRH plus GHRP-6 induced a clear increase in GH secretion with a peak at 15 minutes of 42.2 +/- 10.0 micrograms/L, which was also unaffected after pretreatment with pyridostigmine (38.4 +/- 5.8 micrograms/L). The GH response was lower in obese patients than in controls as assessed by the area under the curve after administration of both GHRH plus GHRP-6 (1,846 +/- 396 v 4,773 +/- 653, P < .01) and pyridostigmine plus GHRH plus GHRP-6 (1,989 +/- 372 v 5,098 +/- 679, P < .005). In conclusion, these data suggest that GHRP-6 can behave as a functional somatostatin antagonist, and that somatotrope responsiveness to the combined administration of GHRH plus GHRP-6 is largely independent of somatostatinergic tone.(ABSTRACT TRUNCATED AT 250 WORDS)
Authors:
F Cordido; A Peñalva; R Peino; F F Casanueva; C Dieguez
Related Documents :
1823078 - Acute effects of clonidine and growth-hormone-releasing hormone on growth hormone secre...
18404598 - Ghrelin as an acute-phase reactant during postoperative stress response.
15137038 - A method for interleaved acquisition of a vascular input function for dynamic contrast-...
15001628 - Postprandial suppression of plasma ghrelin level is proportional to ingested caloric lo...
21864518 - Complementarily of urine analysis and serum free light chain assay for assessing respon...
15862568 - Long-term treatment of ghrelin stimulates feeding, fat deposition, and alters the gh/ig...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Metabolism: clinical and experimental     Volume:  44     ISSN:  0026-0495     ISO Abbreviation:  Metab. Clin. Exp.     Publication Date:  1995 Jun 
Date Detail:
Created Date:  1995-07-14     Completed Date:  1995-07-14     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0375267     Medline TA:  Metabolism     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  745-8     Citation Subset:  IM    
Affiliation:
Faculty of Medicine, University of Santiago de Compostela, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Drug Combinations
Female
Growth Hormone / blood*
Growth Hormone-Releasing Hormone / pharmacology*
Humans
Obesity / blood*
Oligopeptides / pharmacology*
Pyridostigmine Bromide / pharmacology*
Reference Values
Chemical
Reg. No./Substance:
0/Drug Combinations; 0/Oligopeptides; 101-26-8/Pyridostigmine Bromide; 87616-84-0/growth hormone releasing hexapeptide; 9002-72-6/Growth Hormone; 9034-39-3/Growth Hormone-Releasing Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Glucocorticoids upregulate high-affinity, high-density lipoprotein binding sites in rat hepatocytes.
Next Document:  Changes in plasma lipoprotein concentrations and composition in response to a low-fat, high-fiber di...